Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US House Bills Address Telemedicine, Prostate Cancer Tests, Diabetes Supplies

Executive Summary

A slate of bills recently approved by the US House Energy and Commerce Health Subcommittee seek to give Medicare stroke beneficiaries better access to telemedicine, provide coverage of DNA-based prostate cancer tests, and make changes to CMS's competitive bidding program for durable medical equipment to ensure diabetic beneficiaries receive diabetes test strips.

You may also be interested in...



Medtech Provisions Approved In US Budget Agreement

Medtech and funding provisions in a two-year budget deal that the US Senate and House approved early Friday morning and which were signed by the President would extend Medicate telehealth programs, remove a rental cap for speech-generating devices and strengthen competitive bidding rules to assure access to diabetic test strips, among others. 

Committees Vote To Secure Kid's Health Funding, But No Device Tax Relief In Sight

Under the gun and past a deadline, Senate and House authorizing committees managed to advance almost-identical bills extending funding for the US Children's Health Insurance Program (CHIP) to full-chamber votes. But no device tax repeal provisions came up amid other demanding political and fiscal priorities, and a Senate staffer says device-tax repeal may be too expensive.

Leveraging mHealth Data For Product Development: FDA-Supported Action Plan Released

Mobile health devices including wearable consumer products have the potential to collect a lot of medical information that can be useful for product development and tracking. A new action plan from US FDA, industry and other key players outlines ways to harness and use that data to bring better products to market more quickly.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT121527

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel